BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Diagnosis
30 results:

  • 1. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
    Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
    Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
    Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
    Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
    Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
    Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Significance of Gene diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug Treatment.
    Yamaguchi H
    J Nippon Med Sch; 2022; 89(5):470-478. PubMed ID: 36351633
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
    de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
    Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With idh Mutations: A Single Center Experience.
    Ambinder A; Smith M; Tsai HL; Varadhan R; DeZern A; Dalton W; Gocke C; Webster J; Gondek L; Gojo I; Ali SA; Huff CA; Swinnen L; Wagner-Johnston N; Showel M; Prince G; Borrello I; Bolaños-Meade J; Luznik L; Jain T; Imus P; Fuchs E; Ambinder R; Gladstone DE; Levis M; Jones R; Ghiaur G; Smith BD
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):260-269. PubMed ID: 34750086
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
    Megherea O; Janes C; Kowalski A; Baron J; Ahn E; Soule A; Newman M
    Leuk Lymphoma; 2021 Dec; 62(13):3219-3225. PubMed ID: 34313176
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Oncogenetic landscape and clinical impact of idh1 and idh2 mutations in T-ALL.
    Simonin M; Schmidt A; Bontoux C; Dourthe MÉ; Lengliné E; Andrieu GP; Lhermitte L; Graux C; Grardel N; Cayuela JM; Huguet F; Arnoux I; Ducassou S; Macintyre E; Gandemer V; Dombret H; Petit A; Ifrah N; Baruchel A; Boissel N; Asnafi V
    J Hematol Oncol; 2021 May; 14(1):74. PubMed ID: 33941203
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A rapid genotyping panel for detection of primary central nervous system lymphoma.
    Gupta M; Burns EJ; Georgantas NZ; Thierauf J; Nayyar N; Gordon A; Jones SS; Pisapia M; Sun Y; Burns RP; Velarde J; Jordan JT; Frigault MJ; Nahed BV; Jones PS; Barker FG; Curry WT; Gupta R; Batchelor TT; Romero JM; Brastianos PK; Marble HD; Martinez-Lage M; Tateishi K; Lennerz JK; Dietrich J; Cahill DP; Carter BS; Shankar GM
    Blood; 2021 Aug; 138(5):382-386. PubMed ID: 33735913
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Germline ALK variations are associated with a poor prognosis in glioma and idh-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular epidemiology of idh2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
    Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
    Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Granular Cell Astrocytoma: A Diagnostic Conundrum.
    Dutta R; Sharma MC; Suri V; Sarkar C; Garg A; Srivastava A; Tandon V
    World Neurosurg; 2020 Nov; 143():209-213. PubMed ID: 32730969
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Current concepts and future directions for hemato-oncologic diagnostics.
    Flach J; Shumilov E; Joncourt R; Porret N; Novak U; Pabst T; Bacher U
    Crit Rev Oncol Hematol; 2020 Jul; 151():102977. PubMed ID: 32446181
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Imaging and Radiologic-Pathologic Correlation in Granular Cell Astrocytomas: Report of 2 Cases.
    Montalvo Afonso A; Darriba Alles JV; Moreno Gutiérrez Á; González Quarante LH; García Leal R; Guzmán de Villoria Lebiedziejewski JA; Sola Vendrell E
    World Neurosurg; 2020 Feb; 134():164-169. PubMed ID: 31698124
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The combination of NPM1, DNMT3A, and idh1/2 mutations leads to inferior overall survival in AML.
    Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
    Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Sparse Representation-Based Radiomics for the diagnosis of Brain Tumors.
    Wu G; Chen Y; Wang Y; Yu J; Lv X; Ju X; Shi Z; Chen L; Chen Z
    IEEE Trans Med Imaging; 2018 Apr; 37(4):893-905. PubMed ID: 29610069
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Case for diagnosis. Infective dermatitis associated with HTLV-1: differential diagnosis of atopic dermatitis.
    Oliveira LML; Souza MV; Guedes ACM; Araújo MG
    An Bras Dermatol; 2017; 92(4):573-574. PubMed ID: 28954118
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors.
    Suzuki A; Maruyama T; Nitta M; Komori T; Ikuta S; Kawamata T; Muragaki Y
    Brain Tumor Pathol; 2017 Oct; 34(4):141-148. PubMed ID: 28823098
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.